10-K · March 31, 2026
Sharps Technology materially pivoted its corporate strategy in 2025, completing a Private Investment in Public Equity (PIPE) of approximately $400 million on August 28, 2025 and allocating the principal holding of its…
Earnings analysis · 10-Q
STSS earnings analysis
Filed May 14, 2026 · Our reading of the company's report
The latest report
Sharps Technology reported a significant net loss of approximately $86 million for Q1 2026, primarily driven by unrealized losses on their Solana (SOL) holdings. Despite a notable increase in revenues to $192,780 from…
Read full summary
Sharps Technology reported a significant net loss of approximately $86 million for Q1 2026, primarily driven by unrealized losses on their Solana (SOL) holdings. Despite a notable increase in revenues to $192,780 from syringe sales, total operating expenses surged, underscoring persistent financial challenges amid a strategic pivot towards digital commodities.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-86.24
- Segment
- Medical Device
- Segment
- Digital Commodities
What stood out
-
Sizeable net loss
The company recorded a net loss of $86,239,232 for Q1 2026, compared to a profit of $1,928,834 in the same period last year.
-
Revenue growth
Revenue from syringe sales was $192,780, a notable growth from $0 in Q1 2025.
-
Strong staking revenue
Net staking revenue amounted to $3,134,109, reflecting success in the digital commodity segment.
-
Increased cash reserves
Cash balance improved to $12,320,547 from $10,382,745 at year-end 2025.
-
R&D and G&A expense increase
R&D expenses reached $137,097, up from none in the prior year; G&A expenses increased by $3.69 million to $5,053,320.
-
Improved working capital position
Working capital rose to $16,160,964 in Q1 2026, up from $14,187,484 at the end of 2025.
What to watch
-
Significant unrealized losses
The company experienced unrealized losses on digital commodity investments totaling $70,846,202.
-
High operational expenses
Total operating expenses rose to $89,390,281 for the quarter, sharply contrasting with Q1 2025 expenses of $1,364,295.
-
Volatility in digital asset market
Risks associated with the fluctuating value of Solana and potential regulatory challenges in the digital commodities market.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · May 15, 2025
Sharps Technology reported Q1 2025 net revenue of $0 and GAAP net income of $1,928,834 (EPS $38.62) versus a net loss of $(982,386) (EPS $(347.50)) in Q1 2024, driven primarily by a $4,618,889 fair value gain on warrant…
10-Q · November 14, 2024
Sharps Technology remains a pre-revenue medical device company: revenue for the period was $0 and the company reported a Q3 net loss of $1,685,060 (−$1.27 per share), an improvement from a Q3 2023 loss of $2,022,344…
10-K · March 29, 2024
Sharps Technology is an early-stage medical device company commercializing ultra-low waste safety syringes. The company reports it "has not generated any revenue to date," incurred net losses of $9,841,638 in 2023 (and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.